{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:38:04Z","timestamp":1790127484447,"version":"4.0.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:00:00Z","timestamp":1609977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:00:00Z","timestamp":1609977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Lenalidomide (LEN) maintenance (MT) post autologous stem cell transplantation (ASCT) is standard of care in newly diagnosed multiple myeloma (MM) but has not been compared to other agents in clinical trials. We retrospectively compared bortezomib (BTZ; <jats:italic>n<\/jats:italic>\u2009=\u2009138) or LEN (<jats:italic>n<\/jats:italic>\u2009=\u2009183) MT from two subsequent GMMG phase III trials. All patients received three cycles of BTZ-based triplet induction and post-ASCT MT. BTZ MT (1.3\u2009mg\/m<jats:sup>2<\/jats:sup> i.v.) was administered every 2 weeks for 2 years. LEN MT included two consolidation cycles (25\u2009mg p.o., days 1\u201321 of 28 day cycles) followed by 10\u201315\u2009mg\/day for 2 years. The BTZ cohort more frequently received tandem ASCT (91% vs. 33%) due to different tandem ASCT strategies. In the LEN and BTZ cohort, 43% and 46% of patients completed 2 years of MT as intended (<jats:italic>p<\/jats:italic>\u2009=\u20090.57). Progression-free survival (PFS; HR\u2009=\u20090.83, <jats:italic>p<\/jats:italic>\u2009=\u20090.18) and overall survival (OS; HR\u2009=\u20090.70, <jats:italic>p<\/jats:italic>\u2009=\u20090.15) did not differ significantly with LEN vs. BTZ MT. Patients with &lt;nCR after first ASCT were assigned tandem ASCT in both trials. In patients with &lt;nCR and tandem ASCT (LEN: <jats:italic>n<\/jats:italic>\u2009=\u200954 vs. BTZ: <jats:italic>n<\/jats:italic>\u2009=\u200984), LEN MT significantly improved PFS (HR\u2009=\u20090.61, <jats:italic>p<\/jats:italic>\u2009=\u20090.04) but not OS (HR\u2009=\u20090.46, <jats:italic>p<\/jats:italic>\u2009=\u20090.09). In conclusion, the significant PFS benefit after eliminating the impact of different tandem ASCT rates supports the current standard of LEN MT after ASCT.<\/jats:p>","DOI":"10.1038\/s41408-020-00390-3","type":"journal-article","created":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T20:03:40Z","timestamp":1610049820000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4000-6904","authenticated-orcid":false,"given":"Marc-Andrea","family":"Baertsch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6226-1252","authenticated-orcid":false,"given":"Elias K.","family":"Mai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hielscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uta","family":"Bertsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans J.","family":"Salwender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Munder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7785-2565","authenticated-orcid":false,"given":"Stephan","family":"Fuhrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"D\u00fchrsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Brossart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Neben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Schlenzka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Kunz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc S.","family":"Raab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Hillenga\u00df","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Jauch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Seckinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Hose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Luntz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Sonneveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk","family":"Lokhorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Goerner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Walter","family":"Lindemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helga","family":"Bernhard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor W.","family":"Blau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christof","family":"Scheid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"Besemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9422-6614","authenticated-orcid":false,"given":"Katja C.","family":"Weisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"H\u00e4nel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"D\u00fcrig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0961-0035","authenticated-orcid":false,"given":"Hartmut","family":"Goldschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"German-Speaking Myeloma Multicenter Group (GMMG)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,7]]},"reference":[{"key":"390_CR1","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","volume":"376","author":"M Attal","year":"2017","unstructured":"Attal, M. et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N. Engl. J. Med. 376, 1311\u20131320 (2017).","journal-title":"N. Engl. J. Med."},{"key":"390_CR2","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1056\/NEJMoa1402888","volume":"371","author":"A Palumbo","year":"2014","unstructured":"Palumbo, A. et al. Autologous transplantation and maintenance therapy in multiple myeloma. N. Engl. J. Med. 371, 895\u2013905 (2014).","journal-title":"N. Engl. J. Med."},{"key":"390_CR3","doi-asserted-by":"publisher","first-page":"230","DOI":"10.6004\/jnccn.2017.0023","volume":"15","author":"SK Kumar","year":"2017","unstructured":"Kumar, S. K. et al. Multiple myeloma, version 3.2017, NCCN clinical practice guidelines in oncology. J. Nat. Comp. Cancer Netw. 15, 230\u2013269 (2017).","journal-title":"J. Nat. Comp. Cancer Netw."},{"key":"390_CR4","doi-asserted-by":"publisher","first-page":"iv52","DOI":"10.1093\/annonc\/mdx096","volume":"28","author":"P Moreau","year":"2017","unstructured":"Moreau, P. et al. Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2020. Annals Oncol. 28, iv52\u2013iv61 (2017).","journal-title":"Annals Oncol."},{"key":"390_CR5","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/leu.2017.211","volume":"32","author":"H Goldschmidt","year":"2018","unstructured":"Goldschmidt, H. et al. Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65\/GMMG-HD4 trial. Leukemia 32, 383\u2013390 (2018).","journal-title":"Leukemia"},{"key":"390_CR6","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1182\/blood-2016-01-693580","volume":"127","author":"P Moreau","year":"2016","unstructured":"Moreau, P. et al. VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial. Blood 127, 2569\u20132574 (2016).","journal-title":"Blood"},{"key":"390_CR7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","volume":"394","author":"P Moreau","year":"2019","unstructured":"Moreau, P. et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. The Lancet 394, 29\u201338 (2019).","journal-title":"The Lancet"},{"key":"390_CR8","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","volume":"35","author":"PL McCarthy","year":"2017","unstructured":"McCarthy, P. L. et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J. Clin. Oncol. 35, 3279\u20133289 (2017).","journal-title":"J. Clin. Oncol."},{"key":"390_CR9","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1056\/NEJMoa1402551","volume":"371","author":"L Benboubker","year":"2014","unstructured":"Benboubker, L. et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N. Engl. J. Med. 371, 906\u2013917 (2014).","journal-title":"N. Engl. J. Med."},{"key":"390_CR10","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","volume":"366","author":"PL McCarthy","year":"2012","unstructured":"McCarthy, P. L. et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N. Engl. J. Med. 366, 1770\u20131781 (2012).","journal-title":"N. Engl. J. Med."},{"key":"390_CR11","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","volume":"366","author":"M Attal","year":"2012","unstructured":"Attal, M. et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N. Engl. J. Med. 366, 1782\u20131791 (2012).","journal-title":"N. Engl. J. Med."},{"key":"390_CR12","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(18)30687-9","volume":"20","author":"GH Jackson","year":"2019","unstructured":"Jackson, G. H. et al. Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 20, 57\u201373 (2019).","journal-title":"Lancet Oncol"},{"key":"390_CR13","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1080\/17474086.2019.1576521","volume":"12","author":"I Vaxman","year":"2019","unstructured":"Vaxman, I. & Gertz, M. Risk adapted post-transplant maintenance in multiple myeloma. Expert Rev. Hematol. 12, 107\u2013118 (2019).","journal-title":"Expert Rev. Hematol."},{"key":"390_CR14","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/leu.2017.256","volume":"32","author":"R Chakraborty","year":"2018","unstructured":"Chakraborty, R. et al. Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation. Leukemia 32, 712\u2013718 (2018).","journal-title":"Leukemia"},{"key":"390_CR15","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/s41409-018-0177-6","volume":"53","author":"J Huang","year":"2018","unstructured":"Huang, J. et al. Lenalidomide vs bortezomib maintenance choice post-autologous hematopoietic cell transplantation for multiple myeloma. Bone Marrow Transpl. 53, 701\u2013707 (2018).","journal-title":"Bone Marrow Transpl."},{"key":"390_CR16","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.mayocp.2013.01.019","volume":"88","author":"JR Mikhael","year":"2013","unstructured":"Mikhael, J. R. et al. Management of newly diagnosed symptomatic multiple myeloma: updated mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus guidelines 2013. Mayo Clinic Proc. 88, 360\u2013376 (2013).","journal-title":"Mayo Clinic Proc."},{"key":"390_CR17","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1182\/blood-2011-09-379164","volume":"119","author":"K Neben","year":"2012","unstructured":"Neben, K. et al. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood 119, 940\u2013948 (2012).","journal-title":"Blood"},{"key":"390_CR18","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3324\/haematol.2013.087585","volume":"99","author":"C Scheid","year":"2014","unstructured":"Scheid, C. et al. Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65\/GMMG-HD4 trial. Haematologica 99, 148\u2013154 (2014).","journal-title":"Haematologica"},{"key":"390_CR19","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","volume":"30","author":"P Sonneveld","year":"2012","unstructured":"Sonneveld, P. et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/ GMMG-HD4 trial. J. Clin. Oncol. 30, 2946\u20132955 (2012).","journal-title":"J. Clin. Oncol."},{"key":"390_CR20","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(18)30687-9","volume":"20","author":"GH Jackson","year":"2019","unstructured":"Jackson, G. H. et al. Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 20, 57\u201373 (2019).","journal-title":"Lancet Oncol"},{"key":"390_CR21","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1038\/leu.2015.80","volume":"29","author":"EK Mai","year":"2015","unstructured":"Mai, E. K. et al. Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma. Leukemia 29, 1721\u20131729 (2015).","journal-title":"Leukemia"},{"key":"390_CR22","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1038\/s41375-020-0724-1","volume":"34","author":"H Goldschmidt","year":"2020","unstructured":"Goldschmidt, H. et al. Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial. Leukemia 34, 1853\u20131865 (2020).","journal-title":"Leukemia"},{"key":"390_CR23","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/s41375-018-0195-9","volume":"33","author":"EK Mai","year":"2019","unstructured":"Mai, E. K. et al. Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma. Leukemia 33, 258\u2013261 (2019).","journal-title":"Leukemia"},{"key":"390_CR24","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BGM Durie","year":"2006","unstructured":"Durie, B. G. M. et al. International uniform response criteria for multiple myeloma. Leukemia 20, 1467\u20131473 (2006).","journal-title":"Leukemia"},{"key":"390_CR25","doi-asserted-by":"crossref","unstructured":"Buuren S van, Groothuis-Oudshoorn K. Mice: multivariate imputation by chained equations in R. J. Stat. Softw. http:\/\/www.jstatsoft.org\/v45\/i03 (2011).","DOI":"10.18637\/jss.v045.i03"},{"key":"390_CR26","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa032290","volume":"349","author":"M Attal","year":"2003","unstructured":"Attal, M. et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N. Engl. J. Med. 349, 2495\u20132502 (2003).","journal-title":"N. Engl. J. Med."},{"key":"390_CR27","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1200\/JCO.2006.10.2509","volume":"25","author":"M Cavo","year":"2007","unstructured":"Cavo, M. et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: bologna 96 clinical study. JCO 25, 2434\u20132441 (2007).","journal-title":"JCO"},{"key":"390_CR28","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1111\/bjh.13994","volume":"173","author":"EK Mai","year":"2016","unstructured":"Mai, E. K. et al. Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial. Br. J. Haematol. 173, 731\u201341. (2016).","journal-title":"Br. J. Haematol."},{"key":"390_CR29","doi-asserted-by":"publisher","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","volume":"7","author":"M Cavo","year":"2020","unstructured":"Cavo, M. et al. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02\/HO95): a multicentre, randomised, open-label, phase 3 study. Lancet Haematol. 7, e456\u2013e468. (2020).","journal-title":"Lancet Haematol"},{"key":"390_CR30","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1200\/JCO.18.00685","volume":"37","author":"EA Stadtmauer","year":"2019","unstructured":"Stadtmauer, E. A. et al. Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: results of the BMT CTN 0702 Trial. JCO 37, 589\u2013597 (2019).","journal-title":"JCO"},{"key":"390_CR31","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","volume":"12","author":"P Moreau","year":"2011","unstructured":"Moreau, P. et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 12, 431\u2013440 (2011).","journal-title":"Lancet Oncol."},{"key":"390_CR32","doi-asserted-by":"publisher","first-page":"964","DOI":"10.3324\/haematol.2015.124347","volume":"100","author":"M Merz","year":"2015","unstructured":"Merz, M. et al. Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial. Haematologica 100, 964\u2013969 (2015).","journal-title":"Haematologica"},{"key":"390_CR33","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S0140-6736(18)33003-4","volume":"393","author":"MA Dimopoulos","year":"2018","unstructured":"Dimopoulos, M. A. et al. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet 393, 253\u2013264 (2018).","journal-title":"Lancet"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-00390-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-00390-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-00390-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T15:38:27Z","timestamp":1669909107000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-00390-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,7]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,1]]}},"alternative-id":["390"],"URL":"https:\/\/doi.org\/10.1038\/s41408-020-00390-3","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,7]]},"assertion":[{"value":"16 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MAB: Takeda: Consultancy, honoraria; Novartis: Consultancy, Research Funding; Celgene, Amgen, Janssen: Travel grants. EKM: honoraria: Janssen, Celgene, Takeda; consulting or advisory role: Janssen, Celgene, Takeda; research funding: Takeda; travel, accommodations, expenses: Janssen, Takeda, Celgene, Mundipharma. TH: no COI. UB: no COI. HJS: Amgen: Honoraria, Other: Travel or accommodations; Bristol-Myers Squibb: Honoraria, Other: Travel or accommodations; Janssen Cilag: Honoraria, Other: Travel or accommodations; Sanofi: Honoraria, Other: Travel or accommodations; Celgene: Honoraria, Other: Travel or accommodations; AbbVie: Honoraria; Takeda: Honoraria, Other: Travel or accommodations. MMu: honoraria: Janssen, BMS, Takeda, Celgene, Amgen; consulting or advisory role: Janssen, BMS, Takeda, Celgene, Amgen; research funding: BMS; travel, accomodations, expenses: Janssen, BMS, Takeda, Amgen. SF: Advisory board: BMS, Celgene und Amgen. UD: Alexion: Honoraria; Janssen: Honoraria. PB: consulting or advisory role: BMS, AMGEN, Roche, MSD; research funding: BMS; travel, accomodations, expenses: BMS. KN: no COI. JS: no COI. CK: no COI. MSR: honoraria: Celgene, BMS,Novartis, Janssen, Takeda; consulting or advisory role: Celgene, BMS,Novartis, Janssen, Takeda; research funding: Celgene, Novartis, AMGEN; travel, accomodations, expenses: Janssen, BMS, Takeda. JH: Advisory boards: Adaptive, Amgen, BMS, Celgene, GSK, Janssen, Oncotracker. AJ: no COI. AS: no COI. DH: no COI. SL: no COI. PS: SkylineDx: Membership on an entity\u2019s Board of Directors or advisory committees; Karyopharm: Research Funding; Amgen: Honoraria, Research Funding; Celgene: Honoraria, Research Funding; Janssen: Honoraria, Research Funding. HL: Janssen: Honoraria, Research Funding; Genmab: Honoraria, Research Funding; Amgen: Honoraria. HM: no COI. MG: no COI. MHo: honoraria: MSD. HWL: no COI. HB: no COI. IWB: research funding: Celgene, BMS, Janssen. CS: honoraria: BMS, Janssen, Celgene, Novartis, Amgen, Takeda; consulting or advisory role: BMS, Janssen, Celgene, Novartis, Amgen, Takeda; speakers bureau: Takeda; research funding: Takeda, Novartis; travel, accomodations, expenses: BMS, Janssen, Celgene, Novartis, Amgen, Takeda. BB: no COI. KCW: honoraria: AMGEN, BMS, Celgene, Novartis, Janssen, Takeda; consulting or advisory role: AMGEN, BMS, Celgene, Juno, Janssen, Adaptive, Sanofi, Takeda; research funding: AMGEN, Celgene, Sanofi, Janssen. MH\u00e4: honoraria: Novartis, Amgen, Roche, Takeda; consulting or advisory role: Celgene. JD: consulting or advisory role: Celgene; speakers bureau: Celgene; travel, accomodations, expenses: Celgene. HG: honoraria: Amgen, BMS, Celgene, Chugai, Janssen, Novartis, Takeda; consulting or advisory role: Amgen, BMS, Celgene, Chugai, Janssen, Novartis, Takeda; speakers bureau: Amgen, BMS, Celgene, Janssen, Novartis, Takeda; research funding: Amgen, BMS, Celgene, Chugai, Janssen, Novartis, Takeda; travel, accomodations, expenses: BMS, Celgene, Janssen, Novartis, Takeda.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"1"}}